Defining a Niche Market Access Strategy: The U.S. Helicobacter Pylori Urea Breath Test (UBT) Market

Defining a Niche Market Access Strategy: The U.S. Helicobacter Pylori Urea Breath Test (UBT) Market

H. Pylori affects 35% of the U.S. population, including 35 million symptomatic patients. Of those, more than 25 million are not receiving appropriate diagnostics and treatments. We are proud to help to advance the market acceptance of the Urea Breath Test and make diagnostics more accessible to patients.

Read on for our analysis of the UBT market, and how we define strategies for other niche markets.

For more information, or to receive a PDF download of this infographic, please contact William Hariri.